Please upgrade your browser.
NCCN has published the NCCN Guidelines for Patients® and NCCN Quick Guide™ for Kidney Cancer, the newest addition to the library of NCCN Guidelines for Patients
Scientists have turned cancerous cells back to normal by switching back on the process which stops normal cells from replicating too quickly
The authors of this study aimed to obtain treatment algorithms and develop decision trees through the analysis of treatment of mccRCC from experts at 11 institutions.
Immunicum presents continued improvement in phase I/II survival data for INTUVAX-treated renal cancer patients
Immunicum reports updated survival data from the Company's phase I/II study in patients with metastatic renal cancer treated with the cancer vaccine INTUVAX.
Through use of a combined proteomic and metabolomic analysis approach, a new paper enhances our understanding of the metabolomic alterations that occur in RCC and highlights new therapeutic targets.
FDA Grants Breakthrough Therapy Designation To Lenvatinib For The Potential Treatment Of Metastatic Renal Cell Carcinoma
Eisai Inc. announced today the U.S. Food and Drug Administration (FDA) granted lenvatinib, the company's multiple receptor tyrosine kinase inhibitor, Breakthrough Therapy designation for the investigational use in patients with advanced or metastatic renal cell carcinoma (RCC) who were previously treated with a vascular endothelial growth factor (VEGF)-targeted therapy.
A new study suggests that patients may not benefit from end-of-life chemotherapy — and that for many, their quality of life may worsen in their final weeks compared with patients who forgo last-ditch treatment.
Although many patients with end-stage cancer are offered chemotherapy to improve quality of life (QOL), the association between chemotherapy and QOL amid progressive metastatic disease has not been well-studied. American Society for Clinical Oncology guidelines recommend palliative chemotherapy only for solid tumor patients with good performance status.
Dr Martin Voss, (Memorial Sloan Kettering Cancer Centre, New York City, USA) talks to ecancertv at ASCO GU 2015 on part 1 of the DART study, a phase II randomised trial using dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma.
Bristol-Myers Squibb Co said a late-stage trial of its drug, Opdivo, was stopped early after the immunotherapy was found to be effective in patients with the most common form of kidney cancer.
|NeonCRM by Neon One|